Hangzhou Bio-Sincerity Pharma-TechLtd Past Earnings Performance
Past criteria checks 2/6
Hangzhou Bio-Sincerity Pharma-TechLtd has been growing earnings at an average annual rate of 41.7%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 48.9% per year. Hangzhou Bio-Sincerity Pharma-TechLtd's return on equity is 10.7%, and it has net margins of 26.7%.
Key information
41.7%
Earnings growth rate
33.5%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 48.9% |
| Return on equity | 10.7% |
| Net Margin | 26.7% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Hangzhou Bio-Sincerity Pharma-TechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,072 | 287 | 135 | 262 |
| 31 Dec 23 | 1,017 | 272 | 138 | 241 |
| 30 Sep 23 | 900 | 250 | 155 | 203 |
| 30 Jun 23 | 786 | 229 | 153 | 184 |
| 31 Mar 23 | 673 | 210 | 131 | 164 |
| 31 Dec 22 | 607 | 194 | 113 | 163 |
| 30 Sep 22 | 573 | 192 | 93 | 149 |
| 30 Jun 22 | 479 | 155 | 75 | 120 |
| 31 Mar 22 | 425 | 126 | 70 | 110 |
| 31 Dec 21 | 374 | 111 | 62 | 78 |
| 30 Sep 21 | 304 | 101 | 51 | 51 |
| 30 Jun 21 | 267 | 85 | 48 | 44 |
| 31 Mar 21 | 211 | 55 | 46 | 36 |
| 31 Dec 20 | 207 | 57 | 50 | 32 |
| 31 Dec 19 | 156 | 44 | 35 | 15 |
| 31 Dec 18 | 82 | 11 | 23 | 12 |
| 31 Dec 17 | 26 | -7 | 10 | 8 |
| 30 Jun 17 | 30 | 8 | 11 | 0 |
| 31 Mar 17 | 27 | 5 | 11 | 0 |
| 31 Dec 16 | 24 | 3 | 12 | 0 |
| 30 Sep 16 | 21 | 1 | 12 | 0 |
| 30 Jun 16 | 16 | -1 | 11 | 0 |
| 31 Mar 16 | 16 | 2 | 8 | 0 |
| 01 Jan 16 | 16 | 5 | 4 | 0 |
| 31 Dec 14 | 6 | -2 | 4 | 0 |
Quality Earnings: 301096 has a high level of non-cash earnings.
Growing Profit Margin: 301096's current net profit margins (26.7%) are lower than last year (31.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301096's earnings have grown significantly by 41.7% per year over the past 5 years.
Accelerating Growth: 301096's earnings growth over the past year (36.7%) is below its 5-year average (41.7% per year).
Earnings vs Industry: 301096 earnings growth over the past year (36.7%) exceeded the Life Sciences industry 1.1%.
Return on Equity
High ROE: 301096's Return on Equity (10.7%) is considered low.